Last reviewed · How we verify

MK-2206 with or without Trastuzumab

QuantumLeap Healthcare Collaborative · Phase 2 active Small molecule

MK-2206 with or without Trastuzumab is a Small molecule drug developed by QuantumLeap Healthcare Collaborative. It is currently in Phase 2 development. Also known as: (Trastuzumab) Herceptin.

At a glance

Generic nameMK-2206 with or without Trastuzumab
Also known as(Trastuzumab) Herceptin
SponsorQuantumLeap Healthcare Collaborative
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MK-2206 with or without Trastuzumab

What is MK-2206 with or without Trastuzumab?

MK-2206 with or without Trastuzumab is a Small molecule drug developed by QuantumLeap Healthcare Collaborative.

Who makes MK-2206 with or without Trastuzumab?

MK-2206 with or without Trastuzumab is developed by QuantumLeap Healthcare Collaborative (see full QuantumLeap Healthcare Collaborative pipeline at /company/quantumleap-healthcare-collaborative).

Is MK-2206 with or without Trastuzumab also known as anything else?

MK-2206 with or without Trastuzumab is also known as (Trastuzumab) Herceptin.

What development phase is MK-2206 with or without Trastuzumab in?

MK-2206 with or without Trastuzumab is in Phase 2.

Related